Free Access
Med Sci (Paris)
Volume 19, Number 10, Octobre 2003
Page(s) 976 - 980
Section M/S Revues
Published online 15 October 2003
  1. Mitchell GA, Grompe M, Lambert M, Tanguay RM. Hypertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited diseases, 8e ed. New York: McGraw-Hill, 2001: 1777–805. [Google Scholar]
  2. Lindsted S, Holme E, Lock EA, Hialmarson O, Strandvik B. Treatment of hereditary tyrosinaemia type 1 by inhibition of 4- hydroxyphenylpyruvate dioxygenase. Lancet 1992; 340: 813–7. [Google Scholar]
  3. De Braekeleer M, Larochelle J. Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay- Lac-St-Jean. Am J Hum Genet 1990; 47: 302–7. [Google Scholar]
  4. Poudrier J, St-Louis M, Lettre F, et al. Frequency of the IVS12+5g: a splice mutation of the fumarylacetoacetate hydrolase gene in carriers of hereditary tyrosinemia in the French Canadian population of Saguenay- Lac-St-Jean. Prenat Diagn 1996; 16: 59–64. [Google Scholar]
  5. St-Louis M, Tanguay RM. Mutations in the fumarylacetoacetate hydrolase gene causing hereditary tyrosinemia type 1: overview. Hum Mutat 1997; 9: 291–9. [Google Scholar]
  6. Arranz JA, Pinol F, Kozak L, et al. Splicing mutations, mainly IVS6-1(g>t), account for 70 % of fumarylacetoacetate hydrolase (FAH) gene alterations, including 7 novel mutations, in a survey of 29 tyrosinemia type I patients. Hum Mutat 2002; 20: 180–8. [Google Scholar]
  7. Poudrier J, Lettre F, Scriver CR, Larochelle J, Tanguay RM. Different clinical forms of hereditary tyrosinemia (type 1) in patients with identical genotypes. Mol Genet Metab 1998; 64: 119–25. [Google Scholar]
  8. Kvittingen EA, Rootwelt H, Brandtzaeg P, Bergan A, Berger R. Hereditary tyrosinemia type 1. Selfinduced correction of the fumarylacetoacetase defect. J Clin Invest 1993; 91: 1816–21. [Google Scholar]
  9. Kvittingen EA, Rootwelt H, Berger R, Brandtzaeg P. Self-induced correction of the genetic defect in tyrosinemia type 1. J Clin Invest 1994; 94: 1657–61. [Google Scholar]
  10. Overturf K, Al-Dhalimy M, Tanguay RM, et al. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinemia type I. Nat Genet 1996; 12: 266–73. [Google Scholar]
  11. Jorquera R, Tanguay RM. Cyclin B-dependent kinase and caspase-1 activation precedes mitochondrial dysfunction in fumarylacetoacetateinduced apoptosis. FASEB J 1999; 13: 2284–98. [Google Scholar]
  12. Kubo S, Sun M, Miyahara M, et al. Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors. Proc Natl Acad Sci USA 1998; 95: 9552–7. [Google Scholar]
  13. Weinberg AG, Mize CE, Worthen HG. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Pediatr 1976; 88: 434–8. [Google Scholar]
  14. Tanguay RM, Jorquera R, Poudrier J, St-Louis M. Tyrosine and its catabolites: From disease to cancer. Acta Biochim Pol 1996; 43: 209–16. [Google Scholar]
  15. Jorquera R, Tanguay RM. The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion. Biochem Biophys Res Commun 1997; 232: 42–8. [Google Scholar]
  16. Jorquera R, Tanguay RM. Fumarylacetoacetate, the metabolite accumulating in hereditary tyrosinemia, activates the ERK pathway and induces mitotic abnormalities and genomic instability. Hum Mol Genet 2001; 10: 1741–52. [Google Scholar]
  17. Gilbert-Barness E, Barness LA, Meisner LF. Chromosomal instability in hereditary tyrosinemia type1. Pediatr Pathol 1990; 10: 243–52. [Google Scholar]
  18. Prieto-Alamo MJ, Laval F. Deficient DNA-ligase activity in the metabolic disease tyrosinemia type I. Proc Natl Acad Sci USA 1998; 95: 12614–8. [Google Scholar]
  19. Kelsey G, Ruppert S, Beermann F, Grund C, Tanguay RM, Schutz G. Rescue of mice homozygous for lethal albino deletions: Implications for an animal model for the human liver disease tyrosinemia type I. Genes Dev 1993; 7: 2285–97. [Google Scholar]
  20. Spear E, Ng DT. The unfolded protein response: No longer just a special teams player. Traffic 2001; 2: 515–23. [Google Scholar]
  21. Yoneda T, Urano F, Ron D. Transmission of proteotoxicity across cellular compartments. Genes Dev 2002; 16: 1307–13. [Google Scholar]
  22. Kaufman RJ. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev 1999; 13: 1211–33. [Google Scholar]
  23. Al-Dhalimy M, Overturf K, Finegold M, Grompe M. Long-term therapy with NTBC and tyrosinerestricted diet in a murine model of hereditary tyrosinemia type I. Mol Genet Metab 2002; 75: 38–45. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.